MedTrace Logo

Gemini Symbicort pMDI

NCT00646516 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 615

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.

Conditions

  • Mild or Moderate Asthma

Interventions

DRUG

budesonide/formoterol (Symbicort)

Sponsors & Collaborators

Principal Investigators

  • Liza O'Dowd, MD · AstraZeneca

  • Catherine Bonuccelli · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2005-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00646516 on ClinicalTrials.gov